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Most antitumor drugs usually affect not only rapidly dividing cells, such as 
those in tumors, but also highly proliferative cells in normal tissues. This 
nonspecific drawback could be successfully solved by using nanocarriers as 
controlled drug delivery systems. In this work, pH and redox-responsive 
nanohydrogels (NG) 
based on N-isopropylacrilamide (NIPA), N-hydroxyethyl acrylamide (HEEA) 2-
acrylamidoethyl carbamate (2AAECM) and N´-N´cystaminebisacrylamide (CBA) 
as crosslinker were evaluated as bioreducible paclitaxel (PTX) nanocarriers for 
improving the accumulation of the drug within the tumor tissue and avoiding its 
conventional side effects. A single dose of PTX solution, unloaded-NHA 
80/15/5CBA NG and PTX-loaded NHA 80/15/5-CBA NG (30mg/kg PTX 
equivalent) were subcutaneously injected in female athymic nude mice bearing 
HeLa human tumor xenografts. PTX-loaded nanohydrogels showed higher 
antitumor activity than free PTX, as tumor evolution and Ki67 detection 
demonstrated. Histological tumor images revealed a higher content of defective 
mitotic figures and apoptotic bodies in PTX- treated tumors than in control or 
unloaded NG treated tumor samples. Nanohydrogels injection did not change 
any biochemical blood parameters, which means no liver or kidney damage 
after NG injection.However, differences in antioxidant defenses in MPS 
systems (liver, kidney and spleen) were observed among treatments, which 
may indicate an oxidative stress response after PTX injection. 
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Cancer is the leading cause of death in economically developed countries and 52 
the second leading cause of death in developing countries. The global impact of 53 
cancer continues to increase largely because of the aging and growth of the 54 
world population alongside an increasing adoption of cancer-causing behaviors, 55 
particularly smoking, in economically developing countries (Jemal et al., 2011). 56 
In the last decades, nanotechnology has emerged to improve the therapeutic 57 
index of existing chemotherapies and radiotherapy treatments which, in 58 
combination with cancer biology advances, can establish new methods for 59 
cancer care (Hull et al., 2014).  60 
61 
Most antitumor drugs affect not only rapidly dividing cells, such as those in 62 
tumors, but also highly proliferative cells in normal tissues. This nonspecific 63 
drawback has limited the clinical application of most anticancer drugs (Li et al., 64 
2009). For instance, paclitaxel (PTX) exhibits a significant activity against 65 
various solid tumors, including advanced ovarian carcinoma, metastatic breast 66 
cancer, non-small cell lung cancer, and head and neck carcinomas 67 
(Panchagnula, 1998; Spencer and Faulds, 1994). It interferes with mitosis by 68 
binding to the β-subunit of tubulin and forming stable, non-functional 69 
microtubule bundles, causing cell death by disrupting the dynamics necessary 70 
for cell division (Crown and O'Leary, 2000). However, its formulation with 71 
Cremophor® EL and ethanol, due to its high hydrophobicity, supposes several 72 
side effects such as hypersensitivity reactions, nephrotoxicity and neurotoxicity 73 
(Singla et al., 2002). Thus, to achieve the necessary therapeutic effect of PTX in 74 
4 
the desired tumor tissue, suitable carriers for PTX are needed. Many vehicles 75 
have been proposed as good candidates for use as controlled delivery systems 76 
(Yared and Tkaczuk, 2012), but few have progressed to in vivo or clinical 77 
studies. 78 
79 
To reach the goal, stimuli-sensitive polymers have been recently studied for 80 
drug delivery (Fleige et al., 2012; Lee et al., 2008), as they can modify their 81 
structural composition/conformation specific cellular/extracellular in response to 82 
chemical, biochemical, or physical stimulus, promoting release of the active 83 
species to specific biological environment (Motornov et al., 2010). For instance, 84 
the high glycolysis showed in solid tumors supposes acidic pH, which can be as 85 
low as 5.7, depending on tumor histology, tumor volume and the location within 86 
a tumor (Engin et al., 1995; Tannock and Rotin, 1989). pH gradient also affects 87 
the ionization, intratumoral distribution and cellular uptake of ionizable drugs in 88 
a tumor (Gao et al., 2005). Thus, a variety of polymeric pH-sensitive 89 
components with cleavable bonds have been described, which contain 90 
reversible ionizable groups, such as carboxylic or amino groups, such as N´-91 
hydroxyethyl acrylamide (HEAA), which allow the swelling of nanogels by 92 
electrostatic repulsion (Blanco et al., 2002; Qiao et al., 2011). Otherwise, it is 93 
also well known that tumor tissues are highly reducing and hypoxic compared 94 
with normal tissues, which means an increase of 7–10 fold higher content of 95 
intracellular glutathione (GSH) in tumor cells than in normal cells (Kuppusamy 96 
et al., 1998). This combination of intracellular elevated GSH and the tumor 97 
associated GSH make redox-responsive nanocarriers interesting candidates for 98 
targeted drug release. These reduction-sensitive polymers and conjugates 99 
5 
show an excellent stability in the circulation and in the extracellular fluids, 100 
whereas they are prone to rapid disintegration under a reductive environment 101 
present in intracellular compartments, such as the cytoplasm and the cell 102 
nucleus (Meng et al., 2009). For this reason, drug delivery systems containing 103 
disulfide linkages such as N, N’-cystaminebisacrylamide (CBA) provide 104 
significant improvements to cytosolic and nucleus drug targeting, where 105 
disulfide linkages are rapidly degraded by GSH (Song et al., 2011). Thus, in the 106 
last decades many engineered nanocarriers have been designed based on 107 
these polymers (Fleige et al., 2012; Klinger and Landfester, 2012; Motornov et 108 
al., 2010). Moreover, nanohydrogels resemble natural living tissue more than 109 
any other class of synthetic biomaterials (Peppas et al., 2000). Their low 110 
interfacial tension reduces their tendency to adsorb proteins from body fluids 111 
and their three-dimensional structure facilitates a faster diffusion into (drug 112 
loading) and out of (drug release) hydrogels to different molecule sizes, which 113 
allows the possible use of these polymeric networks as drug delivery systems 114 
(Gupta et al., 2002). 115 
In our previous work, new stimuli-responsive nanohydrogels based on poly-N-116 
isopropylacrilamide (NIPA),N-hydroxyethyl acrylamide (HEAA) and tert-butyl 2-117 
acrylamidoethyl carbamate (2AAECM) were synthesized by a microemulsion 118 
polymerization method using N,N-cystaminebisacrylamide (CBA) as a 119 
crosslinking agent, to obtain bioreducible drug carriers for PTX encapsulation 120 
(Perez et al., 2014). Cell culture studies revealed effective and cytocompatible 121 
nanocarriers for hydrophobic anticancer drugs delivery, such as paclitaxel. 122 
Thus, in this study, the in vivo anti-tumor effect of those PTX-loaded 123 
nanohydrogels was investigated by using female athymic nude mice bearing 124 
6 
HeLa human tumor xenografts to insure maximal therapeutic efficacy with 125 
minimal side effects, increasing drug residence at the target site and improving 126 
cellular uptake and intracellular stability. 127 
128 





















Sodium hydroxide (NaOH), hydrochloric acid (HCl; 37%), sodium chloride 
(NaCl), ethanol absolute, xylene, Triton X-100, phosphoric acid (85% w/
v) anhydrous di-sodium hydrogen phosphate (Na2HPO4) and di-
hydrogen potassium phosphate (KH2PO4) were purchased from Panreac 
(Barcelona, Spain). Bovine serum albumin (BSA, Fraction V) and 
disodium hydrogen phosphate dehydrated were purchased from Merck 
(Barcelona, Spain).Paclitaxel (Taxol) was supplied by Tocris Bioscience (Mw 
889.95 > 99%). Paraformaldehyde, Commasie-blue G-250 and gentamicin were 
purchased from Sigma–Aldrich (Barcelona, Spain). Dulbecco’s modified Eagle 
medium + GlutaMax (DMEM) was purchased from Lonza (Belgium). 0.05% 
trypsin/0.53 mM EDTA, penicillin and streptomycin were purchased from 
Invitrogen Life Technologies (Grand Island, NY). Hydrogen peroxide solution 
was obtained from Fluka. All water used in the biochemistry analysis was 
Millipore Milli Q grade. All the chemicals used were of the highest commercially 
quality available
























Copolymeric nanohydrogels of N-isopropylacrylamide (NIPA), N-hydroxyethyl 
acrylamide (HEAA) and 2-acrylamidoethyl carbamate (2AAECM) (Agüero et al., 
2010) using N-N´-cystaminebisacrylamide (CBA) as the crosslinking agent were 
obtained by microemulsion polymerization, as described before (Perez et al., 
2014). In the present study, we evaluate the nanohydrogel formulation 
composed by NIPA/HEAA/2AAECM-CBA 80:15:5:5 namely as NHA 80/15/5-
CBA.
After the purification process, paclitaxel (PTX) was encapsulated by immersion 
of 50 mg of the nanogel in a PTX/ethanol solution (10 mg/mL) at room 
temperature (22◦C) in the dark for 24 h. The suspension was then centrifuged at 
7,000 rpm for 5 min (Digicen20-R Ortoalresa Centrifuge, Radius 8.2 cm rotor; 
Madrid, Spain) and the pellet dried (Bioblock Scientific 45001, France) until the 
ethanol had completely evaporated. The amount of PTX loaded in the 
nanosystems was determined by high-performance liquid chromatography 
(HPLC) as described in our previous work (Perez et al., 2014). All quantifications 
were performed in triplicate and drug encapsulation efficiency (%) was 
calculated as previously described (Perez et al., 2014).  
Zeta potential of unloaded- and PTX-loaded nanohydrogels was analyzed from 
a dispersion of those nanosystems in distilled water (Zeta Potential Analyzer, 
Brookhaven, Ins.Corp.). 
2.3. In vivo antitumor efficacy studies 
- Cell culture. Human cervical cancer cells (HeLa) were cultured and
maintained in DMEM+GlutaMax-I supplemented with 10% heat inactivated172 
8 
fetal bovine serum, penicillin (50 U/mL), streptomycin (50 µg/mL) (Invitrogen 173 
Life Technologies, Grand Island, NY, USA) and gentamicin (50 µg/mL) 174 
(Sigma–Aldrich Company, United Kingdom) in a humidified incubator at 37◦C 175 
and 5% CO2 atmosphere (HERA cell, Sorval Heraeus, Kendro Laboratory 176 
Products GmbH, Hanau, Germany). Cells were plated in 75 cm2 flask 177 
(Sarstedt Ag and Co., Barcelona, Spain) and were passaged when reaching 178 
95% confluence by gentle trypsinization (0.05% trypsin/0.53 mM EDTA; 179 
Invitrogen Life Technologies). The cells were harvested during the logarithmic 180 
growth phase and re-suspended in serum free medium before inoculation in 181 
animals. 182 
- Experimental model. The experimental protocol involving use of animals was183 
approved by the Institutional Animal Care and Use Committee of Complutense184 
University of Madrid. Female athymic mice (Nu/Nu strain), 4–6 weeks old,185 
weighing  20 ± 3g were purchased from Harlan Laboratories (Indianapolis,186 
USA) and were housed under controlled laboratory conditions in187 
polycarbonate cages having free access to sterilized rodent pellet diet and188 
water ad libitum. The animals were allowed to acclimate for at least 48 hours189 
before any experiments.190 
191 
- Subcutaneous tumor xenograft development. 9 x 106 HeLa cells,192 
suspended in 200 µl of serum free medium were injected subcutaneously into193 
the dorsal side of mice under light isoflurane anesthesia. Palpable solid tumors194 
developed within 14-16 days post tumor cell inoculation and as soon as tumor195 
volume reached ~140 mm3, the animals were randomly allotted to four196 
different groups (6 animals per group): control (saline serum), free PTX in197 
9 
and PTX-loaded NHA 198 aqueous solution, unloaded-NHA 80/15/5-CBA NG 






















- In vivo administration of the formulations. Six lightly-anesthetized animals
per group were used for the experiments. Each lightly-anesthetized tumor-
bearing animal received PTX at a single dose of 30 mg/ kg either in aqueous
solution or in PTX-loaded NHA 80/15/5-CBA nanohydrogels (30mg/kg of PTX
equivalent) by subcutaneous administration (200 µL) in the surroundings of
tumor.
- Evaluation of therapeutic efficacy. Animal weight was recorded three times
a week. The tumor diameters were also measured three times weekly with
vernier calipers in 2 dimensions. Individual tumor volumes (V) were calculated
using the formula: V = [length x (width)2]/2 where length (L) is the longest
diameter and width (W) is the shortest diameter perpendicular to length.
Moreover, tumor volume evolution was divided into two different stages f(rom
day 14 to day 30; and from day 30 to day 39) in order to calculate tumor growth
rate in those periods of time (V2: 14-30, V3: 30-39). The tumor growth ratio for
each phase was calculated using the tumor growth rate established in the first
phase, before treatments (V1; V1 = 12.9 mm3/day (r2= 0.97)) (Table 1).
Following the completion of treatment schedule, mice were sacrificed and
tumors were isolated, weighted and post-fixed in paraformaldehyde 4% for
histopathological and immunohistochemical analysis. Plasma samples, liver,
kidney, spleen, lung, heart, ovary and uterus were also collected, weighted and


























2.4. Tumor histology and Immunohistochemistry Studies 
After the post-fixation step, tumors were washed by successive dipping in 
ethanol and xilene, and embedded in Paraplast® (Surgipath®, Leica). For 
histological observations, the tumors were cut into 8 µm sized sections using a 
microtome blade, fixed on the glass slide for overnight at 37 ◦C, and mounted 
using glass coverslip for observation under a microscope. The tumor sections 
were analyzed for histology by optical microscopy using the alcian blue 
hemalum picro-indigo, the toluidine blue, and the hematoxylin–eosin methods 
(Humason, 1979). 5 µm sized tumor sections were cut in order to develop 
immunohistochemical studies. These studies were carried out using the Ki-67 
labeling test (Patel and Amiji, 1996). Ki-67, a nuclear antigen expressed in 
proliferating cells and absent in resting cells, was qualitatively determined 
incubating the samples with purified mouse anti-human Ki-67 antibody (1:25, 
BD Biosciences Pharmingen, USA) and revealed them after by a fluorescence 
method. After the incubation with the mouse antihuman Ki-67 antibody, samples 
were incubated with a rabbit antimouse-rhodamine as second antibody (1:100, 
BD Biosciences Pharmingen), then washed and mounted with Dapi-
Fluoromount-G (SouthernBiotech, AL, USA) for observation by light 
fluorescence microscopy. To ensure specific staining of the Ki-67 positive cells, 
some tissue sections were treated only with the second antibody. 
2.5. Blood biochemistry analysis and Oxidative Stress 
Once collected blood in heparin tubes, plasma was obtained by centrifugation 

























aspartate aminotransferase (AST), alanine aminotransferase (ALT) and 
alkaline phosphatase (ALP); and kidney functions: blood urea nitrogen (BUN) 
and creatinine (CRE). Assays were performed by enzyme assay kits 
(Biosystems®, Spain) and data were obtained using a spectrophotometer 
(Evolution 201, Thermo Scientific, Spain). 
Otherwise, once organ samples were extracted, they were frozen (-80ºC) for 
later enzymatic activity analysis, in order to evaluate antioxidant defenses. For 
this purpose, tissue samples from liver, kidney and spleen were weighted and 
homogenized (Heidoloph RZR 2050 electronic) at 1200 rpm in ice-cold 
NaCl 0.9% (w/v) and 10µL heparin. The homogenates were mixed with four 
volumes of Triton X-100 (1%, v/v) and the residual fragments were 
removed by centrifugation at 12,500 rpm for 15 min. Later, total antioxidant 
capacity (TAC; Oxiselect™, Cell Biolabs, Inc.), superoxide dismutase 
activity (SOD; Oxiselect™, Cell Biolabs, Inc.), total glutathione (Oxiselect™, 
Cell Biolabs, Inc.) and glutathione reductase activity (Abnova, UK) were 
performed by enzyme assay kits. Catalase activity  was determined by 
following Aebi method (Aebi, 1984): 60µL serum was mixed with 1mL of 
peroxide hydrogen 3% (w/v) diluted in phosphate buffer (50Mm, pH 7). 
Finally, total protein was assayed by Bradford method (Bradford, 1976).  
2.6. Statistical data analysis 
Results were expressed as a mean ± standard deviation (SD). Statistical 
analysis was performed using one way analysis of variance (ANOVA) 
following by Bonferroni post hoc analysis with computer software SPSS 22.0.  270 
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3.1. Preparation and characterization of nanohydrogels 275 
Nanohydrogel drug content studies showed a loading capacity of 47.4 ± 5.4 µg 276 
PTX/mg NG, and an encapsulation efficiency of 48.5%. Besides, zeta potential 277 
evaluation revealed anionic surface in both unloaded and drug loaded 278 
nanohydrogels (-2.75 mV in unloaded NHA 80/15/5-CBA NG and -18.11 mV in 279 
PTX-loaded NHA 80/15/5-CBA NG). 280 
3.2. In vivo antitumor efficacy studies 281 
In order to evaluate the safety of the treatments, body weight was monitored 282 
during the period of experiment. Results showed that body weight of all animals 283 
increased normally with age (Fig. 1), with no differences among groups. 284 
Moreover, no significant changes were found in organosomatic index in any of 285 
the animal groups (Fig. 2).  286 
Tumor volume was measured every two days until day 39 in order to evaluate 287 
the tumor evolution (Fig.3). Neither toxicity-induced death nor complete tumor 288 
growth regression was observed in any experimental group.  289 
As shown in Fig.3, tumor volume increased rapidly when the mice were treated 290 
with saline serum or unloaded NHA 80/15/5-CBA nanohydrogels. Little 291 
differences were found between the tumor evolution of these two groups. Tumor 292 























correlation value (r2). During the first stage (14-30 days), a slower tumor growth 
rate was observed (21.9-42.6 mm3/day for control and unloaded-NG groups, 
respectively), with a tumor growth ratio of 1.7-3.3 respectively. During the 
second stage (30-39 days), a rapid tumor growth of 94.5-58.5 mm3/day was 
seen, which corresponds to 7.3-4.5 tumor growth ratios. In the case of tumors 
treated with PTX (free PTX and PTX-loaded nanohydrogels) significant 
differences (p<0.01) were obtained when compared with control saline group 
(Fig.3). Additionally, the antitumor activity of PTX-loaded nanohydrogel 
treatment was higher than the observed in free PTX treated mice (Fig.3), which 
was in accordance to tumor growth rate and ratio. As observed in Table 1, 
tumor growth rate showed two different stages, with a good correlation value 
(r2), where free PTX group demonstrated a more rapid tumor growth (33.0 
mm3/day at the first stage and 36.9 mm3/day at the second stage) than in PTX-
loaded NG group (20.6 mm3/day at the first stage and 8.01 mm3/day at the 
second stage). Moreover, tumor growth at the second stage was the slowest 
growth rate during the whole experiment, with a tumor growth ratio of 0.6.  
3.3. Tumor histology and Immunohistochemistry Studies 
To further evidence the observed anticancer activity, the tumor tissues of mice 
either untreated or treated were subjected to histological observation, 
employing the hematoxylin-eosin (Fig. 4), the toluidine blue and the alcian 



























As it can be observed in Fig. 4, the epithelial-like cortex of the untreated 
and unloaded nanohydrogels-treated tumors (Fig. 4 a-d) was composed of 
poorly cohesive heterogeneous cells, mostly polyhedral in shape, with 
a large nucleus/cytoplasm index. In these images, some nucleus revealed a 
dispersed chromatin and prominent nucleoli, although mitosis was also 
observed. Moreover, images showed a low presence of connective tissue 
and some necrosis areas. An extensive lymphocyte infiltration into tumor 
tissue was also shown. 
Otherwise, differences in tumor histology could be observed in the tumor 
cells of the epithelial-like cortex of PTX-loaded nanohydrogels treated mice, 
as well as free PTX treated animals. First, Figs. 4e-h images showed an 
increase in the amount of defective mitotic figures, observed as hyperchromatic 
objects (yellow circles) and several apoptotic bodies (black square), and 
necrosis areas (red arrow). In addition, the tissue seems to be more 
retracted and higher disorganized than untreated tumors (Fig. 4e and g).  
Additionally, in order to differentiate proliferating cells remaining in the tumor 
tissue from dead cell populations, Ki-67 cell proliferation assay was carried 
out by immunohistochemical staining of the tumor sections (Fig.5).Thus, 
the presence of the antigen was visualized using a fluorescence dye 
(fluorescence microscopy). As it is shown in Fig. 5E and F, the highest 
fluorescent signals of Ki67 antigen were obtained from tumors treated with 
free paclitaxel, which was similar to that obtained in untreated and unloaded 
treated tumors (Fig. A.2). In contrast, very low fluorescent signal was 
observed in case of PTX-loaded 
341 
15 
nanohydrogel samples (Fig.5 B and C). This result means a lower presence of 342 
the antigen in these tissues, even in the blood vessel surrounding area, and 343 
therefore an enhanced antitumor activity efficacy of the drug. 344 
345 
3.4. Blood biochemistry analysis and Oxidative Stress 346 
Potential pathological lesions in liver and kidney induced by the administration 347 
of nanohydrogels can be characterized by an increase in biochemical 348 
parameters including the liver and the kidney function markers. Thus, various 349 
biochemical serum parameters were tested from both treated and untreated 350 
animals. As shown in Table 2, no significant differences (p <0.05) were obtained 351 
among control group and nanohydrogel treatments in AST, ALP, BUN and CRE 352 
levels. Nevertheless, a significant increase (p <0.05) of ALT activity was 353 
observed in free-PTX treated animals, when compared with control group and 354 
PTX-NHA 80/15/5-CBA treatment. Furthermore, a significant decrease (p 355 
<0.05) in creatinine levels was observed in free PTX treated mice, when 356 
compared with control group and PTX-NHA 80/15/5-CBA treatment. 357 
Otherwise, oxidative stress is proposed as one of the most important 358 
mechanisms for nanotoxicity. Thus, to evaluate a possible association among 359 
oxidative response with nanohydrogels injection, different antioxidative 360 
parameters were evaluated in liver, kidney and spleen (Fig.6). Results obtained 361 
from antioxidant defenses analysis in the liver revealed a significant decrease 362 
(p< 0.05) in superoxide dismutase (SOD) and catalase activities (CAT) in PTX 363 
solution and PTX-NHA 80/15/5-CBA treatment groups. In the case of kidney, 364 

























activities. However, a significant increase (p< 0.05) in GSSG-R activity 
was observed in spleen samples extracted from PTX-loaded NG mice, 
comparing with control group. Moreover, a significant increase in total 
glutathione content (GSSG/GSH) was also observed in free PTX and PTX-
loaded NG groups at kidney samples.  
4. Discussion
Controlled drug delivery systems release bioactive agents at 
predetermined rates for predefined periods of time and have been used to 
overcome the shortcomings of conventional drug formulations (Qiu and 
Park, 2012). As observed in our previous in vitro work (Perez et al., 2014), 
NHA 80/15/5-CBA nanohydrogels may be used as potential carriers for PTX 
delivery in order to increase its solubility and reach a pharmacological 
concentration, avoiding the side effects of the conventional formulation 
(Reul et al., 2011). In vitro characterization showed nanoscale spherical 
hydrogels (in the size range of 10-80 nm at physiological conditions). In vitro 
drug release studies revealed an incomplete PTX release from those 
nanohydrogels along the first 50 hours, with a maximum PTX release of 
58.8% (19.74 ± 2.39 µg/mg NG). Two different stages were observed during 
this period: a rapid drug release within the first 5h and a more controlled drug 
release in the last 45h of the experiment. In this previous work (Perez et al., 
2014), a tight dependence between the amounts of the drug released from 
particles and the pH and GSH medium levels was observed. In a release 
medium without GSH, results showed a more rapid drug release at pH 5 
(1.39 µg PTX/h) due to electrostatic repulsion between a protonated amino 



























and, therefore, a faster drug release. Nevertheless, the most rapid PTX release 
was obtained in an intracellular GSH concentration medium (K value between 
1.86 µg PTX/h −2.15 µg PTX/h). These data revealed that this accelerated PTX 
release from nanohydrogels might be due to the reduction of crosslinking agent 
(CBA) disulfide linkages by GSH content. Here, we evaluate the safety and the 
effectiveness of those nanosystems in vivo in a xenograft tumor model. Results 
indicated there were no significant differences in body weight changes among 
the experimental groups during the experimental time period (Fig.1). The mice 
receiving PTX-loaded NHA 80/15/5-CBA nanohydrogels showed similar body 
weight curves to the saline-treated mice, which implied that NHA 80/15/5-CBA 
nanohydrogels did not have severe toxicity in regards to body weight changes. 
Besides, organosomatic index results (Fig.2) also demonstrated no significant 
differences among treatments, which may be interpreted according to the safety 
and effectiveness of these nanosystems in the tumor treatment. Moreover, 
those results were also in accordance to zeta potential analysis results, which 
revealed a negative surface charge. As several authors demonstrated (Mayer et 
al., 2009; Sharifi et al., 2012), anionic surface seems to be less hematotoxic 
than cationic surface particles, as positively charged particles showed higher 
affinity to the negative phospholipid head groups or protein domains on cell 
membranes (Goodman et al., 2004). 
In order to confirm the anti-tumor effect of PTX-loaded nanohydrogels, the mice 
were treated with nanohydrogels and free PTX at a single dose of 30mg/kg. As 
expected, no significant tumor regression was observed in the placebo-



























anti-tumor activity (Fig.3). Moreover, tumor growth rates and tumor growth ratio 
of unloaded nanohydrogels group demonstrated a rapid evolution of the 
tumor at the final stage, which was similar to control saline group (Table 1). 
In our study, tumor growth rates and ratios were lower in PTX-loaded 
nanohydrogel group than in free PTX group during the whole experiment (Table 
1). When PTX was freely administered in solution, tumor seemed to stop 
growing during the first stage (14-30 days), as observed when tumor growth 
rate (33.0 mm3/day) was compared with tumor growth rate of unloaded-NG 
group (42.6 mm3/day); however, the antitumor activity of free-PTX was not 
effective enough to cause the stabilization of tumor growth. After the day 30, 
tumors treated with free PTX recovered its capacity of proliferation, 
reaching a tumor growth rate (36.9mm3/day) similar to those obtained 
at the first stage in control and unloaded-NHA 80/15/5-CBA NG groups. In 
addition, tumor growth suppression was observed in PTX-loaded 
nanohydrogel group (Fig.3; Table 1) in the last nine days of the experiment 
(from day 30 to day 39), as expected for sustained and controlled drug release 
in the targeted tumor sites and tumor cells. These results could be explained 
by the rapid degradation of free PTX within the tumor tissue site by hydrolytic 
process (Iqbal et al., 2011), while PTX loaded in nanosystems was 
protected from hydrolytic degradation, maintaining drug concentration 
within the therapeutic window (Zhang et al., 2013). These results were in 
accordance to Chun et al. studies (Chun et al., 2009), and 
demonstrated that PTX-loaded nanohydrogels require more time for cellular 
uptake and drug release than free PTX for effective tumor inhibition, and 




These in vivo antitumor effects confirmed that PTX-loaded nanohydrogels could 440 
improve the chemotherapeutic efficacy of free PTX, according to Shim et al. 441 
(Shim et al., 2007) study, where PTX was encapsulated in pH and temperature 442 
hydrogels and subcutaneously injected into C57BL/6 male mice at 25 and 50 443 
mg/kg PTX dose. This improved antitumor effect may be explained by the 444 
increasing drug residence at the target site due to the high cellular uptake and 445 
intracellular stability, as demonstrated in previous studies (Perez et al., 2014). 446 
Once the drug vehicle reaches the cell, the particle is shuttled from the early 447 
endosome to the late endosome and finally the lysosome for degradation 448 
(Steichen et al., 2013). Throughout this pathway the pH decreases from 7.4 to 449 
approximately 5.0, leading to the expansion of these cationic nanogels, due to 450 
the charge repulsion between neighboring protonated amine groups of HEAA 451 
monomer as observed in our previous work (Perez et al., 2014). Consequently, 452 
a faster drug release was obtained. Additionally, contained within the 453 
intracellular components are enzymes and GSH molecules that aid in foreign 454 
body degradation (Steichen et al., 2013). Moreover, PTX was mainly released 455 
from these nanocarriers once CBA crosslinking hydrogel desintegration 456 
occurred, by disulfide linkages reduction in the presence of GSH, which means 457 
a reduction of side effects by targeting to disease site and target cells.  458 
Otherwise, particles in the size range of 20–200nm, such as these 459 
nanohydrogels (10–80 nm in the collapsed state) (Perez et al., 2014), could 460 
easily extravasate through endothelial pores (50–100 nm in size) and 461 
accumulate inside the interstitial space for a long time, due to the inefficient 462 
lymphatic drainage observed in the solid tumors (Kwon et al., 2008; Steichen et 463 
al., 2013). This size also provides increased diffusivity, biodistribution, absence 464 
20 
of immunogenicity, and the ability to target specific tissues with minimal 465 























Histological analysis, using both routine and immunohistochemical staining 
methods, is a common procedure for obtaining pathological information (Fig. 4). 
Tumor sections from PTX-loaded nanohydrogels treated mice and free PTX 
treated mice showed a high density of defective mitotic cells, apoptotic bodies, 
as well as necrosis areas. These results were in accordance to the microtubule 
depolymerization process carried out by taxanes. Microtubules are 
heterodimeric α/β-tubulin filaments implicated in diverse cellular functions 
beyond cell division, such as growth, motility, the development and 
maintenance of cell shape, and the trafficking of vesicles, organelles, and 
proteins (Andreopouloua and Muggia, 2008). Paclitaxel acts to stabilise 
microtubules, causing the cell cycle arrest at the G2/M checkpoint of mitotically 
active cells (Kumar et al., 2015) as showed in our previous work (Perez et al., 
2014); thereby it inhibits cell replication, which in turn results in apoptosis 
(Panchagnula, 1998), according with the results obtained from free PTX and 
PTX-loaded nanohidrogels (Fig. 4). Furthermore, recent studies from glioma 
stem cells after PTX treatment showed that polymorphic nuclei signs such as 
the presence of defective mitotic figures, uncondensed chromatin threads, 
chromosome fragmentation and de-condensed chromosomes were time-
dependent (Riva et al., 2014).This mitotic activity is a crucial parameter to 
measure the aggressiveness of a tumor and it is therefore associated with 
important clinical implications. Thus, various biological parameters are routinely 


























nuclear protein Ki67, which has demonstrated strong prognostic effects and has 
been predictive of a greater response to most chemotherapies (Tozuka et 
al., 2013). Our results revealed a lower presence of this tumor proliferation 
indicator in PTX-loaded NHA 80/15/5-CBA nanohydrogel treated tumors, 
compared with untreated or free PTX treated tumors (Fig. 5). These 
results, together with tumor evolution analysis suggested that PTX-
loaded NHA 80/15/5 CBA nanohydrogel was the most effective treatment. 
Moreover, our water-soluble PTX-nanohydrogel formulation is Cremophor-
free. The same conclusions were obtained from a study by Shim et al. 
(Shim et al., 2007) where PTX-loaded block copolymer subcutaneous 
injectable hydrogel could effectively suppress the tumor proliferation, as 
revealed immunohistological apoptotic cells detection. Also, Liu et al. 
(Liu et al., 2008) showed similar results after intravenous injection of 
PTX-loaded carbon nanotubes (5 mg/kg) in 4T1 tumor-bearing Balb/c mice.  
Most of the injected nanoparticles are taken in and eliminated by 
mononuclear phagocyte system (MPS), including liver and kidney tissue 
(Li and Huang, 2008.). Moreover, drug biodistribution results obtained from 
different research groups (Kim et al., 2001; Liu et al., 2008; Wang et al., 2013; 
Zhang et al., 2008) demonstrated PTX was mainly distributed in spleen, 
kidney and liver tissues and the most antitumor drugs affect not only rapidly 
dividing cells such as those in tumors, but also those in highly proliferative 
normal tissues (Lia et al., 2009).Thus, various biochemical parameters and 
antioxidant defenses were tested in order to analyze potential pathological 
lesions in those organs induced by the injection of NHA 80/15/5-CBA 



























blood parameters (Table 2) revealed no liver or kidney damage in unloaded 
nanohydrogel treated mice and PTX-loaded treated nanohydrogel mice, as 
ALT, AST, ALP, BUN and CRE levels were similar to those obtained from 
control-saline group and in good agreement with the reference normal ranges 
for mice (Chen et al., 2003; Pagel et al., 2003; Wang et al., 2013). Similar 
conclusions were obtained by Wang et al. studies (Wang et al., 2013) where 
PTX loaded PEGylated poly(ɛ-caprolactone-co-L-lactide) micelles were 
intravenously injected in S180 tumor-bearing mice at different PTX dosage (10, 
20 and 30 mg/kg). In contrast, free PTX-treated mice showed a significant 
increase of alanine aminotransferase activity (ALT) and a significant decrease 
of creatinine blood level. These results may indicate liver and kidney damage 
after free PTX injection and were in accordance with Mo-ying et al. studies (Mo-
ying et al., 2004), which revealed liver injuries in S-180 mice after PTX injection. 
Authors also observed that the mechanisms of the liver injuries are correlated 
with oxidative stress after administration of the drug.  
As mentioned above, a little amount of these subcutaneously 
administrated nanohydrogels, as well as their residual bodies, may 
extravasate through endothelial pores (50–100 nm in size) and achieve MPS 
organs, such as liver, kidney or spleen. Therefore, in the present study, 
oxidative stress response was also evaluated after nanohydrogels injection 
(Fig. 6). Oxidative stress occurs when there is an excess of free radicals 
in the body, which are constantly produced in normal physiological 
conditions during metabolic processes in all living species (Sharifi et al., 
2012). Nevertheless, an excessive reactive oxygen species (ROS) 
accumulation will lead to cellular injury, ending up in many physiological 



























inflammation and cardiovascular disease (Oberdörster et al., 2005). To prevent 
that, tissues have developed an antioxidant defense system that includes 
non-enzymatic antioxidants such total glutathione content (GSSG/GSH) 
and enzymatic activities like SOD, CAT and GSSG-R (Simmons, 1984). Our 
results revealed lower activity levels of SOD and CAT in the liver of 
subcutaneous administered free PTX solution group and in the PTX-loaded 
nanohydrogels treated group, in comparison to control group, indicating 
higher level of oxidative stress due to PTX injection (Fig. 6). Similar results 
were obtained by Kalaria et al. (Kalaria et al., 2009), where doxorubicin 
solution as well as doxorubicin-loaded PLGA nanoparticles were orally 
and intravenously administrated in female Sprague–Dawley rats. 
Thus, significant changes on SOD and CAT activities in the liver of athymic 
mice after PTX solution and PTX-loaded nanohydrogels injection were 
observed.  SOD scavenges O2 –• anion (which is the first product of 
oxygen radicals) to form H2O2 and, therefore, diminishes the toxic effects due to 
the free radicals derived from secondary reactions. Besides, the O2 –• anion 
inactivates CAT activity, which is a major determinant of hepatic anti-
oxidant status, involved in detoxification of high H2O2 concentrations (Zhang 
and Kwong-Huat, 2000). Thus, a low SOD activity means a decrease in 
CAT function, as observed in our results. Moreover, the decrease observed in 
SOD activity could be due to a damage of enzymatic structure, function 
or enzymatic gene expression (Szymonik-Lesiuk et al., 2003). The liver is 
involved in numerous metabolic, immunological and endocrine functions with 
high blood vasculature. Despite the fenestration size depends on the animal 
species, it is known that sinusoidal fenestrae in C57BL/6 mice are 141 nm 
size (Jacobs et al., 2010), 
564 
24 
which allows unrestricted passage of plasma components and nanohydrogels 565 
(10–80 nm size range at physiological conditions) to the perisinusoidal space 566 
,where the cords of hepatocytes are situated (Bertrand and Leroux, 2012). 567 
Inside the sinusoid capillaries, nanohydrogels could be phagocyted by the 568 
Kupffer cells, via the recognition of opsonins on the nanohydrogels surface, 569 
using fluid phase pinocytosis or endocytosis, due to their small size (Champion 570 
et al., 2008; Petros and DeSimone, 2010). After ingestion, phagocytic vesicles 571 
(phagosomes) coalesce with intracellular organelles containing digestive 572 
proteins and an acidic internal pH, which may suppose a faster PTX release 573 
from nanocarriers according to the cationic response of these nanohydrogels 574 
(Perez et al., 2014) and the desintegration of the internalized polymeric 575 
nanohydrogels. After desintegration, these nanosytems could be eliminated by 576 
exocytosis or sequestered in residual bodies within the cell if it cannot be 577 
digested (Bertrand and Leroux, 2012).  578 
579 
Besides, these drug delivery systems containing disulfide linkages such as N, 580 
N’-cystaminebisacrylamide (CBA) can be reduced by glutathione molecule, as 581 
in vitro studies demonstrated (Perez et al., 2014). In the present study, a 582 
significant increase in GSSG-R activity was observed in spleen samples after 583 
the treatment with PTX-loaded nanohydrogels (Fig. 6). Glutathione reductase 584 
(GSSG-R) is involved in the maintenance of glutathione in reduced form (GSH) 585 
by catalyzing the reduction of GSSG to GSH in the presence of NADPH (Zhang 586 
and Kwong-Huat, 2000). As described above, the resulting GSH helps protect 587 
cells from free radical damage by acting as an antioxidant non enzymatic agent. 588 


























crosslinking agent (CBA) by reducing disulfide linkages of nanogel structure, as 
observed in our previous in vitro studies (Perez et al., 2014). As 
a consequence, glutathione reductase activity increases to maintain the 
normal GSSG-GSH counterbalance. 
Finally, kidney samples showed a significant increase of total 
glutathione content (GSSG/GSH; Fig.6) in PTX-treated animals (free PTX and 
PTX-loaded nanohydrogels). As other authors observed before (Mohamed 
et al., 2014; Valko et al., 2006), oxidative stress response could induce an 
increase of total glutathione content by increasing its synthesis. These 
results could be explained by the kidneys function, as they are responsible 
for blood filtration. This occurs through the glomerular capillary network of the 
glomerulus, one of its components is the highly fenestrated endothelium. The 
fenestration size (60 to 80 nm) makes difficult most of particulate drug delivery 
systems to be filtered; consequently they could be retained (Bertrand and 
Leroux, 2012) modifying the normal counterbalance of ROS production and, in 
this way, the total glutathione content. 
5. Conclusions
Nowadays, paclitaxel administration is associated with several side effects such 
as hypersensitivity reactions, nephrotoxicity and neurotoxicity. In this study, we 
have investigated the antitumor effect of PTX-loaded nanohydrogels to 
overcome those side effects from conventional formulation. The results showed 
that a single dose of PTX (30 mg/kg) when administered in NHA 80/15/5-
CBA stimuli-responsive nanohydrogels, led to significant enhancement of 



































model, with less toxicity than free PTX administration, as measured by changes 
in blood biochemistry analysis. Based on these results, systemic administration 
of PTX in biodegradable polymeric nanohydrogels delivery system could 
be considered as a very effective strategy to be evaluated in further in vivo 
assays in order to achieve the necessary therapeutic effect of PTX, and 
overcome drug 
resistance in cancer patients. 
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V1 represents tumor growth rate before PTX treatment; V1 = 12.9 mm3/day. V2 represents tumor growth rate among the day 14 to 30. 
V3 represents tumor growth rate among the day 30 to 39. 
Table 1. Tumor growth rate (mm3/day) and tumor growth ratio. T (days) indicates 
the time, in days, considered in each analyzed phase. Two different stages were 
observed (stage I: from day 14 to day 30; stage II: from day 30 to day 39) 
along the tumor evolution experiment period.  
Treatments T(days) 





14-30 V2/V1= 1.7 
30-39
 21.9 (0.912)  
94.5 (0.989) V3/V1= 7.3 
Unloaded NHA 80/15/5-CBA 
14-30 V2/V1= 3.3 
30-39
 42.6 (0.969)  
58.5 (0.959) V3/V1= 4.5 
Free PTX 
14-30 V2/V1= 2.6 
30-39
 33.0 (0.985)  
36.9 (0.947) V3/V1= 2.9 
PTX-NHA 80/15/5-CBA 
14-30 V2/V1= 1.6 
30-39
 20.6 (0.900)  
8.01 (0.956) V3/V1= 0.6 
Table 1
All data are the mean ± SD (n=6). 
* P < 0.05 when compared with the normal saline (control group).
+
 P< 0.05 when compared with PTX-NHA 80/15/5-CBA. 
Table 2. Biochemical blood analysis of female athymic nude mice bearing HeLa human tumor 
xenografts after treatments: untreated (control) and treated with unloaded-NHA 80/15/5 CBA, 
PTX-NHA 80/15/5-CBA and free PTX at the dose of 30mg/kg. AST: aspartate 
aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; BUN: blood urea 
nitrogen and CRE: creatinine.  
Treatment AST (U/L) ALT (U/L) ALP (U/L) BUN (mg/dL) CRE (µmol/L) 
Control 244.5 ± 48.8 31.7 ± 2.4 113.0 ± 33.7 18.7 ± 0.2 53.4 ± 2.6 
Free PTX 294.9 ± 31.1 84.4 ± 7.9*+ 168.8 ± 31.0 21.5 ± 2.8 27.1 ± 2.6*+ 
Unloaded NHA 80/15/5- CBA 178.3 ± 44.7 23,3 ± 4.7 154.7 ± 58.4 19.2 ± 3.3 47.9 ± 2.3 
PTX-NHA 80/15/5-CBA 157.2 ± 21.2 39.7 ± 13.3 160.5 ± 40.1 18.7 ± 2.8 36.9 ± 3.5 
Table 2
Figure 1. Mean body weight change in female athymic nude mice bearing HeLa human tumor 
xenografts treated with either saline, unloaded  nanohydrogels, PTX-loaded nanohydrogels or PTX 
at a dose of 30 mg/kg subcutaneously injected (dark arrow). Each point represents mean ± SD 
(n=6). 
Time (days)
























Figure 2: Organosomatic index of the organs extracted from female athymic nude 
mice bearing HeLa human tumor xenografts after the different treatments. All data 
are the mean ± SD (n=6).  





































* p < 0.01 when compared with the normal saline.
Figure 3. Antitumor effect of unloaded nanohydrogels (NHA 80/15/5-CBA), PTX-loaded 
nanohydrogels (PTX-NHA 80/15/5-CBA) and free PTX in female athymic nude mice bearing 
HeLa human tumor xenografts. Two weeks after subcutaneous HeLa injection, treatments were 
injected subcutaneously in a single dose (black arrow). Untreated control received saline serum 
injection; the treatments groups consisted in unloaded nanohydrogels, PTX-loaded 
nanoparticles and free PTX (considering PTX concentration 30 mg/kg). All data are the mean ± 
SD (n=6). 
Time (days)

































Figure 4. Histological appearance of the epithelial-like cortex of HeLa cell untreated tumor (a-b), unloaded NHA 80/15/5-CBA nanohydrogels treated tumor (c-
d); PTX-loaded NHA 80/15/5-CBA nanohydrogels treated tumor (e-f) and free PTX treated tumor (g-h), using the hematoxylin-eosin staining method 
(magnifications 10x and 40x). Yellow circles indicate the presence of cells in different stages of mitotic division. Arrows indicate the presence of necrosis areas 















Control Unloaded NHA 80/15/5 CBA PTX-NHA 80/15/5-CBA Free PTX 
Figure 4
Figure 5. Representative images of the immunohistochemical detection of Ki-67 
antigen (proliferation assay) in HeLa xenograft tumor samples using the fluorescent 
method: PTX-loaded nanohydrogel treated tumor (A-C) and free PTX treated tumor 
tissues (D-F). In blue is represented the nuclear staining with DAPI. In red, the nuclear 
fluorescent signal due to the presence of Ki-67 proliferating antigen. Overlay indicates 
the visualization of both co-staining images. Arrows indicate the presence of some Ki-
67 positive nuclei in tumor tissues. White bars represent 100µm. 
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All data are the mean ± SD (n=6). * p < 0.05 when compared with the normal saline (control group). 
Figure 6: Antioxidant determinations from liver, kidney and spleen of female athymic nude mice 
bearing HeLa human tumor xenografts after treatments. (a) superoxide dismutase activity 
(SOD); (b) catalase activity (CAT); (c) glutathione reductase activity (GSSG-R) and (d) total 
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Highlights 
 PTX-loaded NG enhanced tumor growth suppression in Hela xenograft models. 
 PTX-NG treated tumors showed apoptotic bodies and several mitotic figures. 
 PTX-NG treated tumors revealed a lower presence of Ki 67 proliferation marker. 
 Biochemical data showed no kidney or liver damage after PTX-NG injection. 








































Figure 5. Representative images of the immunohistochemical detection of Ki-67 
antigen (proliferation assay) in HeLa xenograft tumor samples using the fluorescent 
method: PTX-loaded nanohydrogel treated tumor (A-C) and free PTX treated tumor 
tissues (D-F). In blue is represented the nuclear staining with DAPI. In red, the nuclear 
fluorescent signal due to the presence of Ki-67 proliferating antigen. Overlay indicates 
the visualization of both co-staining images. Arrows indicate the presence of some Ki-
67 positive nuclei in tumor tissues. White bars represent 100µm. 
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